Posted inDermatology news Oncology
KEYVIBE-010: Why Adding TIGIT Inhibition to Pembrolizumab Failed to Benefit High-Risk Resected Melanoma Patients
The Phase 3 KEYVIBE-010 trial demonstrates that adding vibostolimab to pembrolizumab in the adjuvant setting for melanoma does not improve outcomes, instead yielding a higher recurrence rate and increased toxicity, reinforcing pembrolizumab monotherapy as the standard of care.